1,3,4-thiadiazole derivatives as PI3Ks inhibitor: design, in silico studies, synthesis, characterization, and antimicrobial evaluation
Turkish Journal of Chemistry · 24.06.2025 · 49 (3) · 325-335
DOI: 10.55730/1300-0527.3732 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Chemistry, online erschienen am 24.06.2025. Verfasst von Dharmvir Singh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Ch. Devilal College of Pharmacy, Jagadhri, Haryana, India. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Since PI3Ks are targeted by a variety of bacterial pathogens, they represent a promising target for host-directed immune therapy and may be beneficial in managing persistent bacterial infections. In the present study, computational studies of 5-(pyridin-4-yl)-1,3,4-thiadiazol-2-amine derivatives for phosphoinositide-3-kinases (PI3Ks) inhibitors were carried out using dock scores, Glide scores, and the MMGBSA dG method, with comparison to standard drugs (ofloxacin and fluconazole). A series of 5-(pyridin-4-yl)-1,3,4-thiadiazol-2-amine derivatives (D1-D17) were synthesized and evaluated for their in vitro antimicrobial activity against both gram-positive and gram-negative bacterial strains, as well as fungal strains, using the tube dilution method. The synthesized compounds were characterized based on their physicochemical properties, and spectral data confirmed consistency with the proposed molecular structures. Docking studies, the MMGBSA analyses, and in vitro antimicrobial activity results indicated that compounds D4, D6, D8, and D12 were the most active against different microbial species and also showed favorable docking results in comparison with the PDB ligand and standard antimicrobial drugs (ofloxacin and fluconazole). This study highlights the potential of these compounds for future in vivo antimicrobial and anticancer investigations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Ch. Devilal College of Pharmacy, Jagadhri, Haryana, India.
- Department of Pharmaceutics, Dharamputra College of Pharmacy, Sonepat, India.
- Department of Pharmacology, Delhi Pharmaceutical Sciences and Research University, New Delhi, Delhi, India.
- Division of Toxicology and Experimental Medicine Division, CSIR-Central Drug Research Institute, Lucknow, India.
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, India.
- Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, H.P, India.
ORCID-Profile: Dharmvir Singh, Pankaj Kumar, Anoop Kumar, Vivek V Bhosale, Kalicharan Sharma, Deepak Kumar, Ramchander Khatri, Tanuj Hooda, Amit Lather
Zitieren
APA
Singh, D., Kumar, P., Kumar, A., Bhosale, V. V., Sharma, K., Kumar, D., Khatri, R., Hooda, T., & Lather, A. (2025). 1,3,4-thiadiazole derivatives as PI3Ks inhibitor: design, in silico studies, synthesis, characterization, and antimicrobial evaluation. Turkish Journal of Chemistry, 49(3), 325-335. https://doi.org/10.55730/1300-0527.3732
Vancouver
Singh D, Kumar P, Kumar A, Bhosale VV, Sharma K, Kumar D, et al. 1,3,4-thiadiazole derivatives as PI3Ks inhibitor: design, in silico studies, synthesis, characterization, and antimicrobial evaluation. Turkish Journal of Chemistry. 2025;49(3):325-335. doi:10.55730/1300-0527.3732
BibTeX
@article{Singh2025,
author = {Singh, Dharmvir and Kumar, Pankaj and Kumar, Anoop and Bhosale, Vivek V and Sharma, Kalicharan and Kumar, Deepak and Khatri, Ramchander and Hooda, Tanuj and Lather, Amit},
title = {1,3,4-thiadiazole derivatives as PI3Ks inhibitor: design, in silico studies, synthesis, characterization, and antimicrobial evaluation},
journal = {Turkish Journal of Chemistry},
year = {2025},
volume = {49},
number = {3},
pages = {325--335},
doi = {10.55730/1300-0527.3732}
}
EUVIMED